Disease Domain | Count |
---|---|
Neoplasms | 10 |
Nervous System Diseases | 3 |
Immune System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Synthetic peptide | 4 |
Diagnostic radiopharmaceuticals | 2 |
Contrast agent | 1 |
Radiolabeled antibody | 1 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GHSR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Mar 2025 |
Sponsor / Collaborator |
Start Date16 Jan 2025 |
Sponsor / Collaborator |
Start Date05 Aug 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
KP-A038 ( RANK ) | Osteoporosis More | Preclinical |
3-DSC ( HMGB1 x factor Xa x thrombin ) | Inflammation More | Preclinical |
64Cu-PCB-TE2A-Tz ( HNRNPA2B1 ) | Triple Negative Breast Cancer More | Preclinical |
Piperine ( MAO-B x PXR ) | Glioblastoma More | Preclinical |
PD-L1Pep-1-K ( PDL1 ) | Neoplasms More | Preclinical |